1-9 of 9
John E. Bisi
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract 5994: INX-315, a potent and selective CDK2 inhibitor, demonstrates robust antitumor activity in CCNE1-amplified cancers

Free
Alec G. Trub, John E. Bisi, Catherine Dietrich, Michael Taylor, Jay C. Strum, Shom Goel, Patrick J. Roberts
Journal: Cancer Research
Cancer Res (2023) 83 (7_Supplement): 5994.
https://doi.org/10.1158/1538-7445.AM2023-5994
Published: 04 April 2023
View articletitled, Abstract 5994: INX-315, a potent and selective CDK2 inhibitor, demonstrates robust antitumor activity in CCNE1-amplified cancers
Journal Articles

Abstract 4426: Selective inhibition of CDK9 induces apoptosis of TNBC cells independent of Rb status

Free
Hailey E. Brighton, Claire R. Hall, Kerry A. Dillon, John E. Bisi, Jay C. Strum
Journal: Cancer Research
Cancer Res (2019) 79 (13_Supplement): 4426.
https://doi.org/10.1158/1538-7445.AM2019-4426
Published: 01 July 2019
View articletitled, Abstract 4426: Selective inhibition of CDK9 induces apoptosis of TNBC cells independent of Rb status
Journal Articles

Abstract 4414: Inhibition of CDK2 overcomes primary and acquired resistance to CDK4/6 inhibitors

Free
Claire R. Hall, John E. Bisi, Jay C. Strum
Journal: Cancer Research
Cancer Res (2019) 79 (13_Supplement): 4414.
https://doi.org/10.1158/1538-7445.AM2019-4414
Published: 01 July 2019
View articletitled, Abstract 4414: Inhibition of CDK2 overcomes primary and acquired resistance to CDK4/6 inhibitors
Journal Articles

Abstract 1522: The CDK4/6 inhibitor G1T38 enhances response to targeted therapies in preclinical models of non-small cell lung cancer

Free
Jessica A. Sorrentino, Daniel M. Freed, John E. Bisi, Jay C. Strum, Patrick J. Roberts
Journal: Cancer Research
Cancer Res (2018) 78 (13_Supplement): 1522.
https://doi.org/10.1158/1538-7445.AM2018-1522
Published: 01 July 2018
View articletitled, Abstract 1522: The CDK4/6 inhibitor G1T38 enhances response to targeted therapies in preclinical models of non-small cell lung cancer
Journal Articles

Abstract 2824: G1T38, a novel, oral, potent and selective CDK4/6 inhibitor for the treatment of Rb competent tumors

Free
Jessica A. Sorrentino, John E. Bisi, Patrick J. Roberts, Jay C. Strum
Journal: Cancer Research
Cancer Res (2016) 76 (14_Supplement): 2824.
https://doi.org/10.1158/1538-7445.AM2016-2824
Published: 15 July 2016
View articletitled, Abstract 2824: G1T38, a novel, oral, potent and selective CDK4/6 inhibitor for the treatment of Rb competent tumors
Journal Articles

Abstract 1784: Pre-clinical characterization of G1T28-1, a novel CDK 4/6 inhibitor for protection of bone marrow from cytotoxic chemotherapies

Free
John E. Bisi, Hannah S. White, Jessica A. Sorrentino, Patrick J. Roberts, Jay C. Strum
Journal: Cancer Research
Cancer Res (2015) 75 (15_Supplement): 1784.
https://doi.org/10.1158/1538-7445.AM2015-1784
Published: 01 August 2015
View articletitled, Abstract 1784: Pre-clinical characterization of G1T28-1, a novel CDK 4/6 inhibitor for protection of bone marrow from cytotoxic chemotherapies
Journal Articles

Abstract 941: G1T28-1, a novel CDK4/6 inhibitor, protects murine hematopoietic stem and progenitor cells from cytotoxic chemotherapy

Free
Jessica A. Sorrentino, Shenghui He, John E. Bisi, Patrick J. Roberts, Jay C. Strum, Norman E. Sharpless
Journal: Cancer Research
Cancer Res (2015) 75 (15_Supplement): 941.
https://doi.org/10.1158/1538-7445.AM2015-941
Published: 01 August 2015
View articletitled, Abstract 941: G1T28-1, a novel CDK4/6 inhibitor, protects murine hematopoietic stem and progenitor cells from cytotoxic chemotherapy
Journal Articles

Abstract 1322: Novel CDK4/6 inhibitors provide robust antitumor activity in a murine model of luminal breast cancer

Free
Patrick J. Roberts, David B. Darr, John E. Bisi, Jay C. Strum
Journal: Cancer Research
Cancer Res (2014) 74 (19_Supplement): 1322.
https://doi.org/10.1158/1538-7445.AM2014-1322
Published: 01 October 2014
View articletitled, Abstract 1322: Novel CDK4/6 inhibitors provide robust antitumor activity in a murine model of luminal breast cancer
Journal Articles

Human Tumor Suppressor ARF Impedes S-Phase Progression Independent of p53

Available to Purchase
Wendell G. Yarbrough, Mika Bessho, Adam Zanation, John E. Bisi, Yue Xiong
Journal: Cancer Research
Cancer Res (2002) 62 (4): 1171–1177.
Published: 01 February 2002
View articletitled, Human Tumor Suppressor ARF Impedes S-Phase Progression Independent of p53
Open the PDF for Human Tumor Suppressor ARF Impedes S-Phase Progression Independent of p53 in another window